Reliable data on long-term drug safety is becoming a growing necessity because drugs are increasingly receiving accelerated approvals based on preliminary evidence or from trials using surrogate endpoints.

We conduct pharmacoepidemiological, disease epidemiology and drug utilization studies to better understand drug safety and utilization to improve patient safety.